Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Mar 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...

Read More

Evaluating the risk of infection associated with ibrutinib treatment in patients with B-cell lymphoma

Posted by on Mar 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma.  This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of...

Read More

Evaluating pembrolizumab plus R-CHOP chemotherapy for patients with untreated diffuse large B-cell lymphoma

Posted by on Mar 10, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that pembrolizumab can be safely added to R-CHOP, with improved survival outcomes. Some...

Read More

Evaluating mental performance in older survivors of non-Hodgkin lymphoma

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated mental functioning in older survivors of non-Hodgkin lymphoma (NHL). This study concluded that these individuals may have some mental function decline and lower mental function compared to individuals who did not have cancer. Some background Research suggests that cancer treatments have been shown to cause...

Read More

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...

Read More

Comparing different sources for stem cell transplantation for patients with lymphoma

Posted by on Feb 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the outcomes of patients with lymphoma who had an allogeneic stem cell transplant with different sources of stem cells. This study found that stem cells from a matching donor had better outcomes compared to those from unrelated cord blood. Some background Allogeneic stem cell transplantation is one type of stem cell...

Read More

Evaluating high-dose methotrexate plus chemotherapy for patients with diffuse large B-cell lymphoma

Posted by on Feb 16, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of treatment with high-dose methotrexate (Trexall) plus chemotherapy for diffuse B-cell lymphoma (DLBCL). This study concluded that this regimen was promising, with manageable side effects for these patients. Some background DLBCL is the most common type of non-Hodgkin’s lymphoma. Initial treatment...

Read More

Evaluating Bendamustine-EAM conditioning chemotherapy for patients with mantle cell lymphoma

Posted by on Feb 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of bendamustine-EAM (Be-EAM) chemotherapy for patients with mantle cell lymphoma (MCL) before a stem cell transplant. This study found that this regimen improved survival outcomes compared to standard regimens. Some background Stem cell transplants (SCT) remain the standard of care for...

Read More

Is R-CVP safer and more effective than R-CHOP for patients with painless NHL?

Posted by on Feb 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two different chemotherapy regimens for patients with indolent (painless) non-Hodgkin’s lymphoma (NHL). This study found that the R-CVP regimen was similarly effective and had fewer side effects compared to R-CHOP for these patients. Some background Chemoimmunotherapy is the...

Read More